| 发明名称 |
Method of administration and treatment |
| 摘要 |
This invention relates to a method of treating cancer in a human in need thereof by determining the presence or absence of a detectable amount of a gene product of the Neurofibromin-2 (NF2) gene in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected. This invention also relates to a method of treating cancer in a human in need thereof, comprising determining the presence or absence of a detectable amount of a functional isoform 1 protein of the NF2 gene, or a functional fragment thereof, in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected. |
| 申请公布号 |
US9192604(B2) |
申请公布日期 |
2015.11.24 |
| 申请号 |
US201214128007 |
申请日期 |
2012.06.28 |
| 申请人 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
发明人 |
Auger Kurt R.;Dar Mohammed M.;Fleming Ronald A. |
| 分类号 |
A61K31/4439;A61K31/535;G01N33/574 |
主分类号 |
A61K31/4439 |
| 代理机构 |
|
代理人 |
Hecht Elizabeth J.;Gimmi Edward R. |
| 主权项 |
1. A method of treating cancer in a human in need thereof, comprising determining the presence or absence of a detectable amount of a gene product of the Neurofibromin-2 (NF2) gene in a sample from said human, and administering to said human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected. |
| 地址 |
Brentford, Middlesex GB |
